Removal of specific N-glycans can alter neutralization potency and completeness. by Sabrina Lusvarghi (2329267)

“…Colors as follow: red, decrease in potency >4-fold; white, no change in IC₅₀ (ratios between 0.25- and 4-fold) and blue increase in potency (ratios <0.25-fold). …”

Structure and growth of the conglobate gland in <i>Blattella germanica.</i> by Viviana Pagone (22086362)

REG-O3 chimeric peptide combining growth hormone and somatostatin sequences improves joint function and prevents cartilage degradation in rat model of traumatic knee osteoarthritis by Rodrick Montjean (400649)

“…The effect of REG-O3, solubilized in a liposomal solution and injected at either 5, 25 or 50 μg/50 μL, was compared to liposomal (LIP), dexamethasone and hyaluronic acid (HA) solutions. …”

Fig 2 - by Mengnan Lu (12128694)

Analysis of reversibility of acoziborole-resistance. by Pieter C. Steketee (10024552)

S6 Fig - by Abishek Balakumar (20189865)

Working model for REG-O3 mechanism of action. by Rodrick Montjean (400649)

Fig 6 - by Altannavch Nyamsambuu (11985176)

SOSV loads in specimens obtained from bats in the SOSV-MARV experimental cohort. by Amy J. Schuh (8520354)

KASV loads in specimens obtained from bats in the KASV-MARV experimental cohort. by Amy J. Schuh (8520354)

Omicron pseudoviruses with oligomannose-type N-glycans are non-infectious. by Sabrina Lusvarghi (2329267)

Plot of adjusted risk ratios of high SARS-CoV-2 viral load upon presentation to the emergency department for each study day compared to the first day of the study that includes an... by Michael J. Satlin (9160569)

Cellular viability of ergothioneine-treated hDPSCs. by Amarin Thongsuk (21485401)

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. …”

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. …”

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. …”

Western blot analysis showing depletion of eIF4A-1 protein in LdPfn^+/-cells, compared to LdPfn^+/+ and LdPfn^+/-comp cells. by Bindu Ambaru (8775299)

The CYP7B1 inhibitor, clotrimazole, and the EBI2 receptor antagonist, NIBR189, attenuate LPS-induced astrocyte migration <i>in vitro.</i> by Fionä Caratis (12759506)

Unusual clinical phenotype of Stargardt disease by Pedro Molina-Solana (12683949)

“…Pattern electroretinogram demonstrated bilateral decrease of p50 values. Genetic testing identified two heterozygous missense mutations, c.428C>T, p.…”

Neuronal activity. by Amarin Thongsuk (21485401)